Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05838586
Other study ID # STEP Up T2D
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date July 31, 2023
Est. completion date July 31, 2026

Study information

Verified date July 2023
Source University of Minnesota
Contact Mary O Whipple, PhD, RN, PHN
Phone 612-625-4470
Email whipp042@umn.edu
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Type 2 diabetes (T2D) confers a high risk of cardiovascular disease (CVD), particularly among older adults who tend to be physically inactive. Prolonged sedentary behavior (SB) has been shown to negatively influence markers of cardiovascular risk (e.g., blood glucose, blood pressure), even among individuals who are physically active. Most studies that have examined the effects of breaking up SB have focused on young healthy males and prioritized glycemic outcomes. Additionally, sex differences in these outcomes have not been adequately examined. The present study will address these gaps. This 3-arm crossover randomized controlled trial will compare the effects of 3 SB conditions on markers of vascular function. The 3 conditions are: 1) 4 hours of prolonged SB, 2) 4 hours of SB broken up by 5 minutes of self-paced walking every hour, and 3) 4 hours of SB with one 20-minute bout of self-paced walking. In addition to examining the overall effects of each condition, sex differences in physiological responses will be evaluated.


Recruitment information / eligibility

Status Recruiting
Enrollment 80
Est. completion date July 31, 2026
Est. primary completion date July 31, 2026
Accepts healthy volunteers No
Gender All
Age group 60 Years and older
Eligibility Inclusion Criteria: - Age =60 years - Postmenopausal (females only, =12 months without a menstrual period) - Type 2 diabetes (hemoglobin A1c =6.5% and/or previous diagnosis of type 2 diabetes) - =6 hours/day sedentary (assessed via IPAQ) - Willingness to abstain from food, caffeine, alcohol and exercise for >= 24 hours, and tobacco/smoking for =12 hours prior to each intervention visit - Ability to speak and read English Exclusion Criteria: - Type 1 diabetes - Uncontrolled hypertension (resting systolic =160 or diastolic =110 mmHg) - Initiation of hormone therapy or change in hormone therapy dose/frequency/route of administration in the previous 3 months - Renal dialysis - History of deep vein thrombosis (DVT) - Evidence of cognitive impairment that could impact ability to consent and/or participation (Mini-Cog score <3) - Achieving physical activity guidelines (=150 minutes of MVPA/week, assessed via IPAQ)) - Physical impairment or disability that interferes with ability to engage in PA (e.g., severe osteoarthritis, lower extremity amputation [other than toe(s)/partial foot], use of a walker or wheelchair, etc.), - Unstable medical/psychiatric condition that could impact study participation

Study Design


Intervention

Behavioral:
prolonged SB
4 hours of prolonged SB
SB broken 1
4 hours of SB broken up by 5 minutes of self-paced walking every hour
SB broken 2
4 hours of SB with one 20-minute bout of self-paced walking

Locations

Country Name City State
United States University of Minnesota Minneapolis Minnesota

Sponsors (1)

Lead Sponsor Collaborator
University of Minnesota

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary iAUC of SBP Net incremental area under the curve (iAUC) of systolic blood pressure (SBP) 90 days
Secondary Net iAUC of DBP Net iAUC of diastolic blood pressure 90 days
Secondary Net iAUC of of MAP Net iAUC of mean arterial pressure 90 days
Secondary Net iAUC of HR Net iAUC of heart rate 90 days
See also
  Status Clinical Trial Phase
Recruiting NCT05650307 - CV Imaging of Metabolic Interventions
Recruiting NCT05654272 - Development of CIRC Technologies
Recruiting NCT04515303 - Digital Intervention Participation in DASH
Completed NCT04056208 - Pistachios Blood Sugar Control, Heart and Gut Health Phase 2
Recruiting NCT04417387 - The Genetics and Vascular Health Check Study (GENVASC) Aims to Help Determine Whether Gathering Genetic Information Can Improve the Prediction of Risk of Coronary Artery Disease (CAD)
Not yet recruiting NCT06211361 - Cardiac Rehabilitation Program in Patients With Cardiovascular Disease N/A
Not yet recruiting NCT06032572 - Evaluation of the Safety and Effectiveness of the VRS100 System in PCI (ESSENCE) N/A
Recruiting NCT04514445 - The BRAVE Study- The Identification of Genetic Variants Associated With Bicuspid Aortic Valve Using a Combination of Case-control and Family-based Approaches.
Enrolling by invitation NCT04253054 - Chinese Multi-provincial Cohort Study-Beijing Project
Completed NCT03273972 - INvestigating the Lowest Threshold of Vascular bENefits From LDL Lowering With a PCSK9 InhibiTor in healthY Volunteers N/A
Completed NCT03680638 - The Effect of Antioxidants on Skin Blood Flow During Local Heating Phase 1
Recruiting NCT04843891 - Evaluation of PET Probe [64]Cu-Macrin in Cardiovascular Disease, Cancer and Sarcoidosis. Phase 1
Completed NCT04083846 - Clinical Study to Investigate the Pharmacokinetic Profiles and Safety of High-dose CKD-385 in Healthy Volunteers(Fed) Phase 1
Completed NCT04083872 - Clinical Study to Investigate the Pharmacokinetic Profiles and Safety of Highdose CKD-385 in Healthy Volunteers(Fasting) Phase 1
Completed NCT03693365 - Fluid Responsiveness Tested by the Effective Pulmonary Blood Flow During a Positive End-expiratory Trial
Completed NCT03619148 - The Incidence of Respiratory Symptoms Associated With the Use of HFNO N/A
Completed NCT03466333 - Postnatal Enalapril to Improve Cardiovascular fUnction Following Preterm Pre-eclampsia Phase 2
Completed NCT04082585 - Total Health Improvement Program Research Project
Completed NCT05132998 - Impact of a Comprehensive Cardiac Rehabilitation Program Framework Among High Cardiovascular Risk Cancer Survivors N/A
Completed NCT05067114 - Solutions for Atrial Fibrillation Edvocacy (SAFE)